Testing a new drug (called MK-4716) when given alone, or in combination with other treatments, in people with advanced or metastatic solid tumoursA Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of MK-4716 as Monotherapy and as Part of Combination Therapy in Participants With KRAS-Altered Advanced or Metastatic Solid Tumors

Exclusion

• Arm MK-4716 + Pembrolizumab: Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention
• Arm MK-4716 + Pembrolizumab: Has received any prior immunotherapy and was discontinued from that treatment
• Arm MK-4716 + Pembrolizumab: Has active autoimmune disease that has required systemic treatment in the past 2 years. Hormonal supplementation (eg, thyroxine, insulin, or physiologic corticosteroid) is allowed
• History of human immunodeficiency virus infection
• Has a known additional malignancy that is progressing or has required active treatment within the past 2 years
• Has a known active central nervous system metastases and/or carcinomatous meningitis
• History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
• Has active infection requiring systemic therapy
• Has Hepatitis B or Hepatitis C virus infection
• History of stem cell/solid organ transplant
• Has not adequately recovered from major surgery or has ongoing surgical complications